Issues of diagnostics and treatment of abdominal pain at irritable bowel syndrome at outpatient stage of the healthcare

The aim of review. To present the diagnostic and treatment algorithm for abdominal pain at out-patient/ polyclinic healthcare institutions and to demonstrate potential of hyoscine butylbromide application during diagnostic process and for relief of abdominal pain at irritable bowel syndrome.

Summary. From 20% to 50% of all admissions to medical institutions are related to abdominal spasms and pain caused by irritable bowel syndrome (IBS). According to the Clinical guidelines of the Russian gastroenterological association and abdominal pain management algorithm at outpatient reception, the doctor on the basis of interviewing, inspection and physical data first of all should exclude acute abdominal diseases (acute pain, parietal pain) requiring urgent examination by the surgeon or gynecologist and subsequent hospitalization. In the case of visceral pain the minimal range of laboratory and instrumental tests is indicated. If the history of visceral pain is more than 6 months and there are no alarm symptoms, doctor should define specific features of clinical presentation already during outpatient visit, taking into account pain location, that provides formulation of preliminary diagnosis. Epigastric pain (dyspepsia), biliary pain, abdominal pain which can be accompanied by impaired frequency and consistency of stool determine the further investigation plan. Implementation of diagnostic algorithm allows to distinguish the organic disease or to establish
the diagnosis of functional disease. Hyoscine butylbromide at short-term treatment will relieve abdominal spasm as a symptomatic agent. Course treatment effectively reduces intensity and frequency of abdominal pain at IBS. The rate of adverse events and tolerability of hyoscine butylbromide are comparable to that of placebo.

Conclusion. Symptomatic treatment by antispasmodic drugs is justified from the moment of referral for medical aid to outpatient department. Hyoscine butylbromide can be prescribed for relief of acute and chronic pain at any stage of diagnostic process. Course intake of antispasmodics has proved its efficacy for pain relief at IBS.

1. Hunt R., Quigley E., Abbas Z., Eliakim A., Emmanuel A., Goh K.L., et al. Coping with common gastrointestinal symptoms in the community: A global perspective on heartburn, constipation, bloating, and abdominal pain/discomfort May 2013. J Clin Gastroenterol 2014; 48(7):567-78.

2. Курилович С.А., Решетников О.В., Пыленкова Е.Д. Абдоминальные симптомы и качество жизни: эпидемиологические аспекты. Рос журн гастроэнтерол гепатол колопроктол 2005; 19(Прил.):156.

3. Peery A.F., Dellon E.S., Lund J., Crockett S.D., et al. Burden of gastrointestinal disease in the United States:2012 update. Gastroenterology 2012; 143(5):117987.e1-3

4. Halder S.L., McBeth J., Silman A.J., Thompson D.G., Macfarlane G.J. Psychosocial risk factors for the onset of abdominal pain. Results from a large prospective population-based study. Int J Epidemiol 2002; 31:1219-25.

5. Ивашкин В.Т., Маев И.В., Кучерявый Ю.А., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по ведению пациентов с абдоминальной болью. Рос журн гастроэнтерол гепатол колопроктол 2015; 25(4):71-80.

6. Baranskaya Ye.K., Shulpekova Yu.O. New colors in abdominal pain palette. Consilium medicum. Gastroenterology 2013; 2:2-5.

7. Tytgat G.N. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 2007; 67(9):1343-57.

8. Samuels L.A. Pharmacotherapy Update: Hyoscine butylbromide in the treatment of abdominal spasms clinical medicine: Therapeutics 2009; 1:647-55.

9. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Осипенко М.Ф., и др. Резолюция Экспертного совета по созданию алгоритма диагностики и лечения абдоминальной боли. Рос журн гастроэнтерол гепатол колопроктол 2015; 25(3):104-6.

10. Mueller-Lissner S., Quigley E.M., Helfrich I., Schaefer E. Drug treatment of chronic-intermittent abdominal cramping and pain: a multi-national survey on usage and attitudes. Aliment Pharmacol Ther 2010; 32:472-7.

11. Lacy B.E., Wang F., Bhowal S., Schaefer E. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. Scand J Gastroenterol 2013; 48:926-35.

12. Ge Z., Yuan Y., Zhang S., Hou X., et al. Efficacy and tolerability of two oral hyoscine butylbromide formulations in Chinese patients with recurrent episodes of self-reported gastric or intestinal spasm-like pain. Int J Clin Pharmacol Ther 2011; 49(3):198-205.

13. Drossman D.A., Li Z., Andruzzi E., et al. U.S. householder survey of functional gastrointestinal disorders, prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38(9):1569-80.

14. Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., Белоусова Е.А., Васильев С.В., Головенко О.В., Головенко А.О., Григорьев Е.Г., Костенко Н.В., Кашников В.Н., Куликовский В.Ф., Лапина Т.Л., Маев И.В., Полуэктова Е.А., Румянцев В.Г., Тимербулатов В.М., Тихонов А.А., Трухманов А.С., Фоменко О.Ю., Халиф И.Л., Хубезов Д.А., Чашкова Е.Ю., Чибисов Г.И., Шептулин А.А., Шифрин О.С., Яновой В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению больных с синдромом раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол 2014; 24(2):92-101.

15. Poynard T., Regimbeau C., Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15(3):355361.

16. Ruepert L., Quartero A.O., de Wit N.J., van der Heijden G.J., Rubin G., Muris J.W. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; 8: CD003460. doi:10.1002/14651858. CD003460.

17. pub3.

18. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt L.J., Chey W.D., Foxx-Orenstein A.E., Schiller L.R., Schoenfeld P.S., Spiegel B.M., Talley N.J., Quigley E.M. An evidencebased position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104 (Suppl. 1):1-35.

19. Ford A.C., Talley N.J., Spiegel B.M., et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and metaanalysis. BMJ 2008; 337:2313.

20. Mueller-Lissner S., Tytgat G.N., Paulo L.G., Quigley E.M., et al. Placebo – and paracetamolcontrolled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. Aliment Pharmacol Ther 2006; 23:1741-8.

21. Longstreth G., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006; 130:1480-91.

22. Khalif I.L., Quigley E.M., Makarchuk P.A., Golovenko O.V., Podmarenkova L.F., Dzhanayev Y.A. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). J Gastrointestin Liver Dis 2009; 18(1):17-22.

23. Pearson J.S., Pollard C., Whorwell P.J. Avoiding analgesic escalation and excessive healthcare utilization in severe irritable bowel syndrome: a role for intramuscular anticholinergics? Ther Adv Gastroenterol 2014; 7(6):232-7.

24. Mueller-Lissner S., Schaefer E.., Kondla A. Symptoms and their interpretation in patients self-treating abdominal cramping with a spasmolytic (Butylscopolamine Bromide). Pharmacol Pharm 2011; 2:82-7.